• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of hematology >Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: A Korea-Japan collaborative study
【24h】

Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: A Korea-Japan collaborative study

机译：韩日合作研究：自体干细胞移植后复发或进展的新生弥漫性大B细胞淋巴瘤患者的同种异体干细胞移植：一项韩日合作研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patients with diffuse large B-cell lymphoma (DLBCL) who failed autologous stem cell transplantation (auto-SCT) generally have a poor prognosis. Allogeneic stem cell transplantation (allo-SCT) has been implemented to overcome this problem. We report clinical outcomes of allo-SCT in patients with de novo DLBCL who failed auto-SCT from four hospitals in Korea and Japan. Thirty patients were included. The median age was 39 (range, 22-59) years. The 5-year event-free survival (EFS) and overall survival (OS) after allo-SCT were 37.9 % and 42.6 %, respectively. There was only a single event beyond 12 months in the Kaplan-Meier curve of EFS. Non-relapse mortality (NRM) was reported in five patients (16.7 %). In the multivariate analysis, the risk factors for EFS were prior chemotherapy lines ≥ 5 (p = 0.010) and chemo-resistant disease (p = 0.007). The risk factors for OS were chemo-resistant disease (p = 0.024) and Eastern Cooperative Oncology Group performance status 2 (p = 0.005). NRM was associated with prior chemotherapy lines ≥ 5 (p = 0.042), chemo-resistant disease (p = 0.009), and poor performance status (p < 0.001). In conclusion, allo-SCT showed considerable efficacy in patients with DLBCL whose disease was relapsed or progressed after auto-SCT. Our data suggest that allo-SCT could be a viable treatment option if patients have fewer lines of prior chemotherapy, chemo-sensitive disease, and/or good PS.
机译：自体干细胞移植（auto-SCT）失败的弥漫性大B细胞淋巴瘤（DLBCL）患者预后较差。异体干细胞移植（allo-SCT）已经被实施以克服这个问题。我们报告了来自韩国和日本四家医院的从头SCT未能通过自动SCT治疗的新生DLBCL患者的allo-SCT的临床结局。包括三十名患者。中位年龄为39岁（22-59岁）。 allo-SCT治疗后的5年无事件生存率（EFS）和总生存率（OS）分别为37.9％和42.6％。 EFS的Kaplan-Meier曲线在12个月后只有一个事件。报告了五名患者（16.7％）的非复发死亡率（NRM）。在多变量分析中，EFS的危险因素是先前化疗≥5（p = 0.010）和化疗耐药性疾病（p = 0.007）。 OS的危险因素是化学耐药性疾病（p = 0.024）和东部合作肿瘤小组的工作状态2（p = 0.005）。 NRM与先前≥5的化疗系（p = 0.042），耐化学性疾病（p = 0.009）和不良的表现状态（p <0.001）相关。总之，同种异体移植对自体SCT术后疾病复发或进展的DLBCL患者具有相当的疗效。我们的数据表明，如果患者先前的化疗方案较少，化学敏感性疾病和/或PS良好，那么allo-SCT可能是一种可行的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号